Conv. Plasma
Nigella Sativa

All convalescent plasma..
Meta analysis
study COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Mortality 8% Improvement Relative Risk Ventilation -2% 7-point scale 22% primary Conv. Plasma  Denkinger et al.  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 134 patients in Germany (September 2020 - January 2022) Improved 7-point scale results with convalescent plasma (not stat. sig., p=0.22) Denkinger et al., Nature Cancer, December 2022 Favors conv. plasma Favors control

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

Denkinger et al., Nature Cancer, doi:10.1038/s43018-022-00503-w
Dec 2022  
  Source   PDF   All   Meta
RCT 134 hospitalized patients showing no significant difference in outcomes with convalescent plasma for all patients, however significantly improved mortality and time to improvement was seen for patients with cancer.
risk of death, 8.2% lower, RR 0.92, p = 0.39, treatment 68, control 66, inverted to make RR<1 favor treatment, day 84.
risk of mechanical ventilation, 2.5% higher, RR 1.02, p = 1.00, treatment 19 of 68 (27.9%), control 18 of 66 (27.3%).
risk of 7-point scale, 22.5% lower, HR 0.78, p = 0.22, treatment 68, control 66, inverted to make HR<1 favor treatment, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Denkinger et al., 29 Dec 2022, Randomized Controlled Trial, Germany, peer-reviewed, 54 authors, study period 3 September, 2020 - 20 January, 2022. Contact:,
This PaperConv. PlasmaAll
Abstract: nature cancer Article Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial Received: 16 September 2022 A list of authors and their affiliations appears at the end of the paper Accepted: 29 November 2022 Published online: xx xx xxxx Check for updates Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with high morbidity and mortality. Furthermore, impaired humoral response renders severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial ( in hospitalized patients with severe COVID-19 (n = 134) within four risk groups ((1) cancer (n = 56); (2) immunosuppression (n = 16); (3) laboratory-based risk factors (n = 36); and (4) advanced age (n = 26)) randomized to standard of care (control arm) or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma (plasma arm). No serious adverse events were observed related to the plasma treatment. Clinical improvement as the primary outcome was assessed using a seven-point ordinal scale. Secondary outcomes were time to discharge and overall survival. For the four groups combined, those receiving plasma did not improve clinically compared with those in the control arm (hazard ratio (HR) = 1.29; P = 0.205). However, patients with cancer experienced a shortened median time to improvement (HR = 2.50; P = 0.003) and superior survival with plasma treatment versus the control arm (HR = 0.28; P = 0.042). Neutralizing antibody activity increased in the plasma cohort but not in the control cohort of patients with cancer (P = 0.001). Taken together, convalescent/vaccinated plasma may improve COVID-19 outcomes in patients with cancer who are unable to intrinsically generate an adequate immune response. The coronavirus disease 2019 (COVID-19)-associated risk of death is particularly high for patients with hematologic or solid cancer1–3, advanced age4,5 and other conditions6,7. Both humoral8 and cellular9 immunodeficiency contribute to unfavorable outcomes. Despite this, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine availability and waning vaccine efficacy in these patients remain concerning10,11. Few therapies improve outcomes in severe COVID-19 with impaired oxygenation12. Monoclonal antibodies as pre- or postexposure prophylaxis or as early treatment can reduce the risk of severe COVID-19 (refs. 13,14). Evidence for the benefit of monoclonal antibodies in patients requiring oxygen supplementation is missing15 or pending16. e-mail:; Nature Cancer Article Randomized (n = 134)a Allocation Allocated to plasma (n = 68) - All received the allocated intervention (n = 68) Allocated to standard of care (n = 66) - All received the allocated intervention (n = 66) Follow-up Lost to follow-up (n = 10)b - At day 14 (n = 1) - At day 28 (n = 2) - At day 56 (n = 2) - At day 84 (n = 5) Lost to follow-up (n = 4)b - At day 14 (n = 1) - At day 56 (n = 3) Discontinued intervention (received only one infusion of..
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop